Skip to content
Loading company

Latest annual · FY2025

Millions
Total revenues
643
Gross profit
444
Operating income
(61)
Net income
(44)
Free cash flow
130

Latest quarter · Q3 FY2026

Millions
Total revenues
151
Gross profit
113
Operating income
(16)
Net income
(19)

Daily close · TXGIEX trades only

Nov 13, 2025 to Nov 11, 2026 · 250 sessions

62.03 USD

020406080100Nov 13, 2025May 14, 2026Nov 11, 2026Vol

Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.

Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms

Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2022 to FY2025
+7.6%
Revenue, 5 yearsFY2020 to FY2025
+16.6%
Net income, 5 yearsFY2020 to FY2025
n/m

10x Genomics, Inc. (TXG) financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2025FY2024ChangeSource
Revenue$642.8 million$610.8 million+5.2%10-K 2026-02-13 · proof
Gross profit$443.9 million$414.5 million+7.1%10-K 2026-02-13 · proof
Operating income-$61 million-$194.6 million10-K 2026-02-13 · proof
Net income-$43.5 million-$182.6 million10-K 2026-02-13 · proof
Cash from operating activities$136.1 million$6.7 million+1,941.6%10-K 2026-02-13 · proof
Free cash flow$130.1 million-$5.7 million10-K 2026-02-13 · proof
Total assets$1 billion$918.6 million+13.4%10-K 2026-02-13 · proof
Total liabilities$245 million$208.5 million+17.5%10-K 2026-02-13 · proof
Cash and cash equivalents$474 million$344.1 million+37.8%10-K 2026-02-13 · proof
What was 10x Genomics, Inc. (TXG)'s revenue in fiscal 2025?
10x Genomics, Inc. (TXG) reported revenue of $642.8 million for fiscal 2025 (the year ended Dec 31, 2025), against $610.8 million the year before (+5.2%). Source: the 10-K filed with the SEC on Feb 13, 2026. SEC
What was 10x Genomics, Inc. (TXG)'s gross profit in fiscal 2025?
10x Genomics, Inc. (TXG) reported gross profit of $443.9 million for fiscal 2025 (the year ended Dec 31, 2025), against $414.5 million the year before (+7.1%). Source: the 10-K filed with the SEC on Feb 13, 2026. SEC
What was 10x Genomics, Inc. (TXG)'s operating income in fiscal 2025?
10x Genomics, Inc. (TXG) reported operating income of -$61 million for fiscal 2025 (the year ended Dec 31, 2025), against -$194.6 million the year before. Source: the 10-K filed with the SEC on Feb 13, 2026. SEC
What was 10x Genomics, Inc. (TXG)'s net income in fiscal 2025?
10x Genomics, Inc. (TXG) reported net income of -$43.5 million for fiscal 2025 (the year ended Dec 31, 2025), against -$182.6 million the year before. Source: the 10-K filed with the SEC on Feb 13, 2026. SEC
What was 10x Genomics, Inc. (TXG)'s cash from operating activities in fiscal 2025?
10x Genomics, Inc. (TXG) reported cash from operating activities of $136.1 million for fiscal 2025 (the year ended Dec 31, 2025), against $6.7 million the year before (+1,941.6%). Source: the 10-K filed with the SEC on Feb 13, 2026. SEC
What was 10x Genomics, Inc. (TXG)'s free cash flow in fiscal 2025?
10x Genomics, Inc. (TXG) reported free cash flow of $130.1 million for fiscal 2025 (the year ended Dec 31, 2025), against -$5.7 million the year before. Source: the 10-K filed with the SEC on Feb 13, 2026. SEC
What are 10x Genomics, Inc. (TXG)'s total assets?
As of Dec 31, 2025, 10x Genomics, Inc. (TXG) reported total assets of $1 billion, against $918.6 million a year earlier (+13.4%). Source: the 10-K filed with the SEC on Feb 13, 2026. SEC
What are 10x Genomics, Inc. (TXG)'s total liabilities?
As of Dec 31, 2025, 10x Genomics, Inc. (TXG) reported total liabilities of $245 million, against $208.5 million a year earlier (+17.5%). Source: the 10-K filed with the SEC on Feb 13, 2026. SEC
What are 10x Genomics, Inc. (TXG)'s cash and cash equivalents?
As of Dec 31, 2025, 10x Genomics, Inc. (TXG) reported cash and cash equivalents of $474 million, against $344.1 million a year earlier (+37.8%). Source: the 10-K filed with the SEC on Feb 13, 2026. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:TXG&period_type=annual&limit=5"

Information only, not investment advice.